跳至主要内容
临床试验/NCT05204810
NCT05204810已完成不适用

Optimisation of Anticoagulation in Patients on Nocturnal Hemodialysis

University Hospital, Ghent1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
Percentage of open fibers in hemodialyzer

研究概览

简要总结

To avoid clotting during extracorporeal treatment, an anticoagulant is added to the circuit, resulting in an increased risk for bleeding complications. In addition, there is evidence that a substantial number of fibers can become blocked before this is reflected in routinely observed parameters, or in termination of the dialysis session.

In standard hemodialysis of 4 hours, the anticoagulant is administered at the beginning of dialysis. For nocturnal hemodialysis, there is no hard evidence whether anticoagulation should be administered only at the dialysis start or with an extra dosing halfway the dialysis session.

The aim of this randomized cross-over study is to objectively quantify the number of patent fibers after nocturnal dialysis in two different settings: anticoagulation only at the dialysis start, and anticoagulation divided over two time points, i.e. dialysis start and halfway dialysis.

详细描述

This single centre, randomized cross-over study includes twenty stable chronic nocturnal hemodialysis patients with no coagulation disorder, active inflammation or chronic cumarin-derived medication.

Patients are randomized over 2 study arms. Each patient is dialyzed over 480min (at midweek) with 2 different settings: anticoagulation only at the dialysis start, and anticoagulation divided over two time points, i.e. dialysis start and halfway dialysis.

For each patient, the dialyzer, the dialysis mode (hemodialysis or hemodiafiltration) and the dialysis settings (blood flow, dialysate flow and substitution flow) are those as currently used by the patient during in-centre nocturnal dialysis.

To determine antiXa, blood samples are taken from the inlet dialysis line at the dialysis start (i.e. 5min after administration of the anticoagulant) and at 1h, 4h and 8h after dialysis start. During the session with 2 anticoagulant administrations, an extra blood sample is taken before as well as after the second anticoagulant administration.

Before the first test session, 1 blood sample is taken to determine antithrombin-III (AT-III).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years or older
  • experienced stable dialysis sessions during the last 4 weeks
  • nocturnal in-centre hemodialysis
  • well functioning vascular access

排除标准

  • known coagulation disorder
  • active inflammation
  • malignancy
  • no coumarin-derived medication

结局指标

主要结局

Percentage of open fibers in hemodialyzer

时间窗: 2 weeks

By scanning the hemodialyzers post dialysis using a reference micro-CT scanning technique, images are obtained from dialyzer cross-sections. Black dots can be counted as open fiber. By counting the number of open fibers and relating this number with the total numerb of fibers in sterile dialyzers, the percentage of open fibers can be quantified.

次要结局

  • Absolute value and change of the clotting parameter antiXa at different time points during dialysis(2 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Strategies for Anticoagulation During Venovenous ECMOAcute Hypoxemic Respiratory FailureAnticoagulant-induced BleedingThromboembolism
NCT04997265Vanderbilt University Medical Center26
招募中
不适用
Optimizing anti coagulant therapy in neurosurgical interventions in patients with an increased risk for thrombo-embolic complications.abnormal blood clottingvasculair illness1000972010014523
NL-OMON55381eids Universitair Medisch Centrum280
撤回
不适用
New Anticoagulation Strategies of VV-ECMOHemorrhage
NCT03497338Xiao Tang
已完成
2 期
the effect of plavix in post coronary artery bypass graft/coronary endarterectomy patientsCoronary artery disease.Atherosclerotic heart disease Coronary (artery): atheroma atherosclerosis disease sclerosis
IRCT2016102730410N2Babol University of Medical Sciences, Deputy of Research & Technology55
进行中(未招募)
1 期
Optimal anticoagulation treatment during percutaneous correction of mitral valve regurgitation and left atrial appendage occlusion utilizing the intra-atrial septum access (STOP CLOT Trial)Mitral regurgitation Atrial fibrilation Periprocedural anticoagulation strategy in patients treated with MitraClip implantation or Left Atrial Appendage Closure. The patients scheduled for MitraClip or LAAC procedure will be randomized to initiation of the unfractionated heparin either 15 minutes before or immediately after transseptal puncture.MedDRA version: 20.0Level: LLTClassification code 10027718Term: Mitral regurgitationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disorders
EUCTR2021-000442-18-PLational Institute of Cardiology410